Academic Journal
Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A 'Campus CML' Study
| العنوان: | Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A 'Campus CML' Study |
|---|---|
| المؤلفون: | Bucelli, C, Capodanno, I, Miggiano, M C, Cavazzini, F, Crescenzi, S Leonetti, Russo, S, Carmosino, I, Annunziata, M, Sorà, F, Bonifacio, M, Luciano, L, Caocci, G, Loglisci, G, Elena, C, Lunghi, F, Mullai, R, Attolico, I, Binotto, G, Crisà, E, Sportoletti, P, Di Veroli, A, Scortechini, A R, Leporace, A P, Maggi, A, Crugnola, M, Stagno, F, Sancetta, R, Murgano, P, Rapezzi, D, Luzi, D, Vincelli, D I, Galimberti, S, Bocchia, M, Fava, C, Malato, A, Abruzzese, E, Saglio, G, Specchia, G, Breccia, M, Iurlo, A, Tiribelli, M, Latagliata, R |
| المساهمون: | Bucelli, C, Capodanno, I, Miggiano, M C, Cavazzini, F, Crescenzi, S Leonetti, Russo, S, Carmosino, I, Annunziata, M, Sorà, F, Bonifacio, M, Luciano, L, Caocci, G, Loglisci, G, Elena, C, Lunghi, F, Mullai, R, Attolico, I, Binotto, G, Crisà, E, Sportoletti, P, Di Veroli, A, Scortechini, A R, Leporace, A P, Maggi, A, Crugnola, M, Stagno, F, Sancetta, R, Murgano, P, Rapezzi, D, Luzi, D, Vincelli, D I, Galimberti, S, Bocchia, M, Fava, C, Malato, A, Abruzzese, E, Saglio, G, Specchia, G, Breccia, M, Iurlo, A, Tiribelli, M, Latagliata, R |
| سنة النشر: | 2024 |
| المجموعة: | Università degli Studi di Cagliari: UNICA IRIS |
| مصطلحات موضوعية: | chronic myeloid leukemia, comorbiditie, dose optimization, efficacy, older, safety, tyrosine kinase inhibitor, very elderly |
| الوصف: | Objectives: The study aimed to evaluate the utilization of frontline TKI therapy in a large cohort of elderly CP-CML patients. Methods: A retrospective analysis was conducted on 332 CP-CML patients aged 75 years or older among 1929 diagnosed from January 2012 to December 2019 followed at 36 participating Hematology Centers involved in the "Campus CML" project. Results: Among the patients analyzed, 85.8% received imatinib (IM) while 14.2% received second-generation TKIs (2G-TKI), 59.5% dasatinib, and 40.5% nilotinib. Most patients initiated IM at standard dose (67.3%) while 32.7% at reduced dose. A similar trend was observed with 2G-TKIs. The cumulative incidence of permanent TKI discontinuation at 12 months was 28.4%, primarily due to primary resistance (10.1%) and extra-hematologic toxicity (9.5%), with no significant difference between IM and 2G-TKI groups. Following the introduction of generic IM in Italy in 2018, IM usage increased significantly compared with 2G-TKIs. Conclusions: IM was in our Centers the preferred frontline therapy for older CP-CML patients, with increasing utilization after the introduction of generic formulations. However, 2G-TKIs are still used in a substantial proportion of patients, suggesting individualized physician assessments regarding patient suitability and expectations. Further investigation is needed to assess efficacy and safety of reduced TKI doses in this patient population. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/39263855; info:eu-repo/semantics/altIdentifier/wos/WOS:001310549900001; numberofpages:8; journal:EUROPEAN JOURNAL OF HAEMATOLOGY; https://hdl.handle.net/11584/414063 |
| DOI: | 10.1111/ejh.14299 |
| الاتاحة: | https://hdl.handle.net/11584/414063 https://doi.org/10.1111/ejh.14299 https://onlinelibrary.wiley.com/doi/10.1111/ejh.14299 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.2A0BF56B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/ejh.14299 |
|---|